Platforms for AAV manufacturing, for Adenoviral vectors, Lentiviral vectors, Oncolytic viruses, Exosomes and for complex recombinant proteins.
Location: Germany, North Rhine-Westphalia, Cologne
Total raised: $19.48M
Investors 2
| Date | Name | Website |
| - | Creathor V... | creathor.c... |
| - | Peppermint... | pvp.health |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.07.2015 | - | $4.92M | - |
| 25.07.2011 | - | $8.62M | - |
| 04.11.2009 | - | $5.94M | - |
Mentions in press and media 19
| Date | Title | Description |
| 27.07.2021 | CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies | DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Financing CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies 27.07.2021 / 14:00 The issuer is ... |
| 30.07.2015 | Daily funding roundup - July 30, 2015 | GitHub raised $250M; Catawiki landed $82M; Golden Gate Ventures announced $50M Git repository hosting service GitHub has just raised a $250 million round of funding, the company has confirmed to VatorNews. The round was led by Sequoia Capit... |
| 30.07.2015 | Cevec Pharmaceuticals Completes €4.5M Financing Round | Cevec Pharmaceuticals GmbH, a Cologne, Germany-based producer of tailor-made recombinant glycoproteins and gene therapy vectors, completed a €4.5m financing round. Backers included new investors Investtodate, Frank Ubags, CEO, and Nicole Fa... |
| 25.07.2011 | CEVEC Pharmaceuticals Closes €6M Financing Round | CEVEC Pharmaceuticals, a Cologne, Germany-based biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns, has closed a €6m financing ro... |
| 04.11.2009 | Germany, CEVEC Pharmaceuticals Close €4M Financing Round | CEVEC Pharmaceuticals GmbH, a Cologne, Germany-based biopharmaceutical company that specializes in developing and producing therapeutic proteins and monoclonal antibodies with human glycosylation patterns, closed a €4m financing round. Crea... |
| - | CEVEC, medac and Provecs Medical enter a collaboration in oncology | Cologne, Wedel and Hamburg, Germany, March 16, 2017 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical co... |
| - | #MakeItTen: Interview with CEVEC Pharmaceuticals | In part №10 of our interview series, we sat down with Dr. Nicole Faust, CEO & CSO of CEVEC Pharmaceuticals to talk about AAV vectors, the importance of enthusiasm for the success of a company, golf and much more. Enjoy reading! |
| - | CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA® in gene therapy | Cologne,Germany, January 8, 2021 - CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of a license agreement with Biogen Inc. (Biogen; Nasdaq: BIIB) for the use of CEVEC’s proprietary ELEVECTA® Technology for the manufacturing o... |
| - | CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies | Cologne, Germany and Philadelphia, PA, USA February 2, 2021 - CEVEC Pharmaceuticals GmbH (CEVEC) and CARISMA Therapeutics Inc. (CARISMA) today announced the signing of an agreement which grants CARISMA a clinical and commercial license for ... |
| - | Cevec signs agreement with Roche for the use of Cevec’s Elevecta® Technology in Gene Therapy | Cologne, Germany, November 10, 2020 - CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of an option and license agreement with Roche for the use of its newly launched ELEVECTA® Technology for large scale manufacturing of adeno... |
Show more